A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of HRS-7249 in Healthy Subjects - a Randomized, Double-blind, Dose-increasing, Placebo-controlled Phase I Clinical Trial

It is a randomized, double-blind, single-dose, placebo-controlled phase I clinical trial. The study plans to conduct four to six dose groups of dose 1, dose 2, dose 3, dose4, dose5 (optional), and dose 6(optional). Eight subjects will be enrolled for each dose group, with six administered HRS-7249 injection and two administered placebo. A total of 32 to 48 healthy subjects are planned to be enrolled.

Study Overview

• Status: Completed
• Conditions: Hyperlipidemia
• Intervention / Treatment: Drug: HRS-7249 injection; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 48
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310009
      • The Second Affiliated Hospital Zhejiang University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Able and willing to provide a written informed consent；
2. Age ≥ 18 and ≤ 65 years old on the day of signing the informed consent ；
3. 0.9 mmol/L≤TG≤5.6 mmol/L；
4. Male or female；
5. Male subjects weigh ≥ 50 kg and < 90 kg , female subjects weigh ≥ 45kg and < 90 kg, and BMI is in the range of 19~30 kg/m2 ；(including boundary values) Normal or abnormality such as vital signs, physical examination and laboratory examination have no clinical significance；
6. Subjects must be willing to use a highly effective method of contraception as deemed appropriate by the investigator throughout the study and for at least 6 months after the last study drug administration.

Exclusion Criteria:

1. Those who suffer from any disease that affects drug absorption, distribution, metabolism, and excretion, or can reduce compliance determined by investigators;
2. Those who suffer from any clinical diseases such as as cardiovascular, liver, kidney, digestive tract, psychiatric, hematological, metabolic abnormalities;
3. A clinically significant history of drug allergies or atopic allergic diseases (asthma, urticaria, eczematous dermatitis);
4. Those with a history of malignant diseases;
5. Those with a history of involving clinical trials of any other drugs or medical devices within the previous 3 months of screening or planned to be conducted during the study period (excluding screening failures), or those who are still within 5 half-lives of the drugs before screening (whichever is longer);
6. Those who have experienced severe trauma or surgery within the previous 6 months, or plan to undergo surgery during the trial period; Serious infected individuals within the previous 3 months of screening;
7. Those who have used any drugs during the screening period or within 2 weeks before the baseline period; or those who are still in 5 half-lives of the drug at the time of screening (whichever is longer);
8. Serum LDL-C ≥ 4.1mmol/L;
9. Platelet count<100 × 109/L;
10. Creatinine≥ upper limit of normal (ULN);
11. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma glutamyltransferase (GGT) ≥2×ULN, or total bilirubin ≥1.5×ULN;
12. During the screening period, human immunodeficiency virus antibodies (HIV-Ab), syphilis serological tests, hepatitis B virus surface antigen (HBs-Ag), or hepatitis C virus antibodies (HCV Ab) is positive;
13. Creatine kinase (CK) ≥ 3 ×ULN;
14. Thyroid stimulating hormone (TSH)< limit of normal (LLN) or≥ 1.5 ×ULN;
15. Glomerular filtration rate (eGFR)<60 mL/min/1.73m2;
16. Urine drug screening positive;
17. Those with a history of blood donation within the previous three months, severe blood loss (blood loss ≥ 400 mL), or who have received a blood transfusion within four weeks;
18. Those who have received the vaccine within the previous two weeks or plan to receive it during the trial process;
19. Those who started new physical exercise or made significantly changed their previous exercise activities within the previous 4 weeks, or who were unable to maintain basic stability in exercise during the study period;
20. Those who have made significant adjustments to their previous diet within the previous 4 weeks, or those whose diet cannot maintain basic stability during the study period;
21. Those who smoke an average of 5 or more cigarettes per day within the previous 4 weeks;
22. In the four weeks before screening, women's daily alcohol intake was more than 15 g, men's more than 25 g and more than twice a week, or the screening period and baseline period alcohol breath test (alcohol blood test can be replaced) was positive;
23. Those with a history of drug use or abuse;
24. Researchers, assistant researchers, research assistants, pharmacists, research coordinators, or other directly involved protocol implementers;
25. The researchers believe that subjects with any unfavorable factors to participate in this experiment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment for intravenously: dose 1	Drug: HRS-7249 injection; 6 subjects for HRS-7249 injection; Drug: Placebo; 2 subjects for placebo
Experimental: Treatment for intravenously: dose 2	Drug: HRS-7249 injection; 6 subjects for HRS-7249 injection; Drug: Placebo; 2 subjects for placebo
Experimental: Treatment for intravenously: dose 3	Drug: HRS-7249 injection; 6 subjects for HRS-7249 injection; Drug: Placebo; 2 subjects for placebo
Experimental: Treatment for intravenously: dose 4	Drug: HRS-7249 injection; 6 subjects for HRS-7249 injection; Drug: Placebo; 2 subjects for placebo
Experimental: Treatment for intravenously: dose 5 (optional)	Drug: HRS-7249 injection; 6 subjects for HRS-7249 injection; Drug: Placebo; 2 subjects for placebo
Experimental: Treatment for intravenously: dose 6 (optional)	Drug: HRS-7249 injection; 6 subjects for HRS-7249 injection; Drug: Placebo; 2 subjects for placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety and tolerability: Incidence of subjects with adverse events (AEs)	Baseline up to Day 169

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics (PK) parameter: AUC0-t for HRS-7249	AUC0-t: Area under the plasma concentration-time curve from time zero to the time of last quantifiable analyte concentration	Baseline up to 48 hours after dosing
Pharmacokinetics (PK) parameter: AUC0-∞ for HRS-7249	AUC0-∞: Area under the plasma concentration-time curve from time zero extrapolated to infinity	Baseline up to 48 hours after dosing
Pharmacokinetics (PK) parameter: Cmax for HRS-7249	Cmax: Maximum plasma concentration	Baseline up to 48 hours after dosing
Pharmacokinetics (PK) parameter: Tmax for HRS-7249	Tmax: Time to reach maximum plasma concentration	Baseline up to 48 hours after dosing
Pharmacokinetics (PK) parameter: t1/2 for HRS-7249	t1/2: Terminal half-life	Baseline up to 48 hours after dosing
Pharmacokinetics (PK) parameter: CL/F of HRS-7249 for administration subcutaneously	CL/F: Apparent clearance	Baseline up to 48 hours after dosing
Pharmacokinetics (PK) parameter: V/F of HRS-7249 for administration subcutaneously	V/F: Apparent volume of distribution	Baseline up to 48 hours after dosing
Pharmacodynamics (PD): TG		Baseline up to Day 169
Pharmacodynamics (PD): HDL-C		Baseline up to Day 169
Pharmacodynamics (PD): LDL-C		Baseline up to Day 169
Pharmacodynamics (PD): non-HDL-C		Baseline up to Day 169
Pharmacodynamics (PD): VLDL-C		Baseline up to Day 169
Pharmacodynamics (PD): TC		Baseline up to Day 169
Pharmacodynamics (PD): Lp(a)		Baseline up to Day 169
Pharmacodynamics (PD): ApoB		Baseline up to Day 169
Pharmacodynamics (PD): ApoA1		Baseline up to Day 169
Immunogenicity: Proportion of anti-drug antibodies (ADA) positive subjects		Baseline up to Day 169

Collaborators and Investigators

• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): August 15, 2024
• Primary Completion (Actual): July 30, 2025
• Study Completion (Actual): July 30, 2025

Study Registration Dates

• First Submitted: July 16, 2024
• First Submitted That Met QC Criteria: August 2, 2024
• First Posted (Actual): August 7, 2024

Study Record Updates

• Last Update Posted (Estimated): September 15, 2025
• Last Update Submitted That Met QC Criteria: September 9, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Dyslipidemias; Lipid Metabolism Disorders; Nutritional and Metabolic Diseases; Hyperlipidemias; Substandard Drugs; Pharmaceutical Preparations; Counterfeit Drugs
• Other Study ID Numbers: HRS-7249-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No